In early clinical data from a Phase 1 trial in esophageal squamous cell carcinoma, the bispecific antibody drug conjugate izalontamab brengitecan reported a confirmed objective response rate of 29.3% across 82 post-treated patients, rising to 39.6% at the 2.5 mg/kg dose, with a disease control rate of 79.2%. Hematologic toxicities, including anemia and thrombocytopenia, were observed but deemed manageable, supporting progression to Phase 3. These signals, although still preliminary, offer the clearest view yet of how dual-targeting ADCs may translate efficacy into solid tumors without incurring prohibitive safety penalties.
The core news is a market inflection point: a new industry analysis projects the first commercial launch of a bispecific ADC by 2029, with more than 100 clinical programs now underway and China driving much of the momentum, with over 60 conjugates under development. The field is coalescing around EGFR/HER3 as a high-value axis, underscored by recent IND clearances for AVZO-1418/DB-1418 in the US and JS212 in China, alongside a steady cadence of platform alliances such as Avenzo–DualityBio and Biohaven–Merus aimed at marrying bispecific scaffolds with topoisomerase-based payloads and advanced linkers.
Strategically, the 2029 launch timeline implies a four-year window to address late-stage risks, including dose optimization and payload choice, class-specific toxicities, and CMC scale-up for complex biologics that combine dual-target binding with cytotoxic delivery. Sponsors are betting that bispecific engagement can improve tumor uptake and overcome resistance seen with single-target ADCs, particularly in solid tumors where penetration and heterogeneity blunt activity. The partnering pattern reveals a pragmatic split: originators focus on discovery and target biology, while CDMOs and platform companies absorb conjugation, linker chemistry, and GMP manufacturing—an acknowledgment that CMC readiness may be as much a gating item as clinical proof.
For sites and CROs, operational complexity will climb. Managing ADC toxicities across dual-target biology requires tighter hematologic monitoring, vigilance for ILD, and dose-modification protocols that may differ from those used in monospecific ADC practice. Trial designs will require harmonized assays to quantify dual-target expression and exposure–response relationships, with a broader use of centralized IHC/NGS and pharmacokinetic modeling to select the RP2D across heterogeneous tumors. As more first-in-human bispecific ADCs move outside Asia, feasibility will hinge on sites with ADC infrastructure, rapid turnaround biomarker testing, and experience in running sentinel cohorts with adaptive dose escalation. CROs and bioanalytical vendors will be pressed to expand immunogenicity, anti-drug antibody, and complex PK assay capacity. At the same time, CDMOs face demand spikes for handling high-potency payloads and supply chains for linkers.
Regulators will expect a more explicit rationale for targets and consistency across populations. The early ESCC signal is encouraging, but durability, safety at commercially relevant doses, and evidentiary pathways beyond ORR will dictate whether accelerated routes are viable. Divergent regulatory timelines between the US, China, and the EU raise practical questions about bridging strategies and companion diagnostic alignment for dual-target selection, which could become a critical path item if assays are not standardized.
Over the next 12 to 24 months, key watch points will include mid-stage readouts for EGFR/HER3 programs, durability curves relative to contemporary ADCs, and whether hematologic toxicity can be managed without compromising dose intensity. On the CMC side, linker stability, DAR consistency, and payload sourcing are potential bottlenecks that could compromise otherwise positive data. If a 2029 launch materializes, it is most likely to come from programs that pair robust biomarker stratification with clean, reproducible manufacturing and early engagement on CDx. The risk, as always with ADC classes, is that incremental efficacy gains are offset by safety or CMC friction. Sponsors that solve for both in parallel—not sequentially—will be the ones to set the regulatory template for bispecific ADCs.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
